Coherus Posts 94% Pegfilgrastim Margin Ahead Of Royalties To Amgen

 
• By Aidan Fry

Coherus has achieved a 94% gross margin on its US sales of biosimilar pegfilgrastim. And while a litigation settlement with Amgen will dilute the margin a little, the biosimilars developer is confident it can keep the margin north of 90%.

Margin
Coherus believes it can maintain US pegfilgrastim gross margins above 90%, even while paying royalties to Amgen • Source: Shutterstock

More from Biosimilars

More from Products